Rigel Pharmaceuticals, Inc.

Total Valuation

Rigel Pharmaceuticals, Inc. carries a market capitalization of 872.72M, placing it among publicly traded companies globally. Its enterprise value stands at 674.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Rigel Pharmaceuticals, Inc. currently has 18.65M shares outstanding.

Valuation Ratios

Rigel Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 2.22. The price-to-sales ratio is 2.59, and the price-to-book ratio stands at 1.72.

Enterprise Valuation

On an enterprise value basis, Rigel Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.52 and an EV/FCF ratio of 6.66. The EV/Sales ratio of 2.44 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.75 provides insight into valuation relative to core operating earnings.

Financial Position

Rigel Pharmaceuticals, Inc. maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.39, indicating elevated leverage, while an interest coverage ratio of 15.45 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Rigel Pharmaceuticals, Inc. has paid -236.33M in income taxes, reflecting an effective tax rate of 52.45.

Stock Price Statistics

Rigel Pharmaceuticals, Inc.'s stock has gained approximately 58.58792% over the past 52 weeks. The 50-day moving average sits at 46.48, while the 200-day moving average is 36.79.

Income Statement

Over the trailing twelve months, Rigel Pharmaceuticals, Inc. generated 276.79M in revenue and converted that into 321.91M in net income, yielding earnings per share of 16.46. EBITDA reached 89.70M, while operating income came in at 87.05M.

Balance Sheet

Rigel Pharmaceuticals, Inc. holds 95.33M in cash and equivalents against 39.95M in total debt, resulting in a net debt position of -21.58M. Total book value stands at 425.42M, with working capital of 89.94M providing operational flexibility.

Cash Flow

Rigel Pharmaceuticals, Inc. produced 79.39M in operating cash flow over the past twelve months.

Margins

Rigel Pharmaceuticals, Inc. operates with a gross margin of 91.39, reflecting its pricing power and cost economics. The operating margin of 31.45 and net profit margin of 116.30 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Rigel Pharmaceuticals, Inc.'s most recent stock split took place on June 27, 2024 with a 10:1 split ratio.

Scores

Rigel Pharmaceuticals, Inc. posts an Altman Z-Score of 2.88, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.